Microglia are an essential component of the neuroprotective scar that forms after spinal cord injury.
Bellver-Landete V, Bretheau F, Mailhot B, Vallières N, Lessard M, Janelle ME, Vernoux N, Tremblay MÈ, Fuehrmann T, Shoichet MS, Lacroix S. · 2019
Read Microglia are an essential component of the neuroprotective scar that forms after spinal cord injury. by Bellver-Landete V, Bretheau F, Mailhot B, Vallières N, Lessard M, Janelle ME, Vernoux N, Tremblay MÈ, Fuehrmann T, Shoichet MS, Lacroix S. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6355913.txt.
Introduction
Bellver-Landete and co-authors show microglia build a protective scar after spinal cord injury. Their study appeared in Nature Communications. Microglia are the spinal cord's resident immune cells. Their role after injury was often confused with macrophages. The team used special mouse lines and depleting drugs. That let them isolate microglia behavior cleanly.
Microglia multiplied fast in the first two weeks. They gathered around the lesion in a dense rim. There they met incoming white blood cells on one side. Astrocytes formed the scar on the other side. Signals from microglia, including IGF-1, guided that scarring. Removing microglia broke the scar apart. More immune cells flooded in, neurons died, and movement recovery suffered. Extra microglia activity helped the opposite way.
Catalog record
| CREATOR | Bellver-Landete V, Bretheau F, Mailhot B, Vallières N, Lessard M, Janelle ME, Vernoux N, Tremblay MÈ, Fuehrmann T, Shoichet MS, Lacroix S. |
|---|---|
| YEAR | 2019 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 89 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Microglia are an essential component of the neuroprotective scar that forms after spinal cord injury By Victor Bellver-Landete, Floriane Bretheau, Benoit Mailhot, Nicolas Vallières, Martine Lessard, Marie-Eve Janelle, Nathalie Vernoux, Marie-Ève Tremblay, Tobias Fuehrmann, Molly S. Shoichet, Steve Lacroix Published in: Nature Communications DOI: 10.1038/s41467-019-08446-0 ABSTRACT The role of microglia in spinal cord injury (SCI) remains poorly understood and is often confused with the response of macrophages. Here, we use specific transgenic mouse lines and depleting agents to understand the response of microglia after SCI. We find that microglia are highly dynamic and proliferate extensively during the first two weeks, accumulating around the lesion. There, activated microglia position themselves at the interface between infiltrating leukocytes and astrocytes, which proliferate and form a scar in response to microglia-derived factors, such as IGF-1. Depletion of microglia after SCI causes disruption of glial scar formation, enhances parenchymal immune infiltrates, reduces neuronal and oligodendrocyte survival, and impairs locomotor recovery. Conversely, increased microglial proliferation, induced by local M-CSF delivery, reduces lesion size and enhances functional recovery. Altogether, our results identify microglia as a key cellular component of the scar that develops after SCI to protect neural tissue. INTRODUCTION Microglia is derived from primitive yolk sac progenitors that arise during embryogenesis1–3. They are maintained after birth and into adulthood by self-renewal4,5, independently from bone marrow-derived hematopoietic stem cells (HSCs) and their differentiated progeny (e.g. monocyte-derived macrophages, MDMs)6,7. After a CNS injury, blood-derived monocytes are massively recruited in the tissue where they differentiate into macrophages and adopt many of the markers and behaviors of microglia. These similarities have complicated the development of efficient prediction tools to discriminate between them. As a consequence, they are still referred to as microglia/macrophages in the neuroscience literature, and accordingly, their individual roles remain to be clarified. Recent advances in genetic fate mapping and conditional gene targeting have allowed the study of the specific biology of microglia in various experimental contexts, including spinal cord injury (SCI)8. This, together with the newly developed strategies to specifically eliminate microglia9, has moved forward knowledge about these cells substantially. For example, the application of some of these advances to a mouse model of stroke has led to the discovery that microglia can protect neurons through the regulation of calcium levels10. In contrast, the elimination of microglia in mouse models of Alzheimer’s disease and Tau pathology reduced disease progression11,12. Thus, depending on the context, microglia may exert diverging roles. Whether these cells are beneficial or deleterious after SCI remains unexplored. Here, we took advantage of Cx3cr1creER mice13, a mouse line that allows with an adequate regimen of tamoxifen to label microglia while excluding nearly all MDMs. Our results show that microglia are highly dynamic and proliferate extensively during the first week post-SCI. Notably, we reveal that microglia form a dense cellular interface at the border of the lesion between reactive astrocytes and infiltrating MDMs, which we hereafter refer to as the “microglial scar”. Microglia depletion experiments using PLX5622, a CSF1R inhibitor that crosses the blood–spinal cord barrier (BSCB), demonstrated that the absence of microglia in the context of SCI disrupts the organization of the astrocytic scar, reduces the number of neurons and oligodendrocytes at the site of injury, and impairs functional recovery. The timing of the beneficial effects of microglia was estimated to be during the first week post-SCI. Accordingly, CNS delivery of M-CSF during that critical period boosted microglial proliferation and enhanced locomotor recovery. In light of these data, we conclude that microglia are an important component of the protective scar that forms after SCI. RESULTS Microglia rapidly accumulate around the site of SCI To distinguish microglia from MDMs, we took advantage of Cx3cr1creER::R26-TdT mice, and the slow turnover of microglia4,5. Mice received tamoxifen treatment one month before SCI to activate the inducible Cre for recombination of TdT floxed (Supplementary Figure 1a). As expected from our previous work14, nearly all (99.6 ± 0.2%) CD11b+ cells in the spinal cord parenchyma expressed TdT (Supplementary Figure 1b, c). In contrast, only a few CD11b+ cells in the blood, spleen and bone marrow were TdT+, with average colocalization percentages of 3.8 ± 1.7%, 6.7 ± 1.6%, and 2.4 ± 0.2%, respectively (Supplementary Figure 1d–f). Thus, inducible Cx3cr1creER::R26-TdT mice are a good tool to study microglia in SCI. To understand the dynamics of the microglial response after SCI, we first quantified the total number of TdT+ microglia both in normal conditions and at 1, 4, 7, 14 and 35 days post-injury (dpi) (Fig. 1a–g and Supplementary Figure 2). In the uninjured thoracic spinal cord of Cx3cr1creER::R26-TdT mice, we counted an average of 85.9 ± 4.6 microglia per mm2. Following a moderate contusive SCI, only 28.8 ± 1.9 microglia per mm2 were left at the lesion epicenter at 1 dpi, which corresponds to a 67% reduction in cell numbers. Hardly any TdT+ microglia were observed in the lesion core at this early time point, suggesting that they underwent rapid cell death. Despite the fact that the impactor tip measures 1.25 mm of diameter, microglia were lost across several spinal cord segments rostrocaudally. This microglial cell loss ranged from ~20% to 65% at rostrocaudal distances up to 6 mm from the lesion epicenter (Fig. 1g, h), and was mediated in part through apoptosis (Fig. 1i–k). At that time, residual microglia still expressed the purinergic receptor P2ry12 (Supplementary Figure 3), a receptor implicated in microglia recruitment during the early acute phase of CNS injury15. Accordingly, we noticed a retraction of microglial processes as early as day 1. Expression levels of the lysosome-associated glycoprotein CD68, a marker of phagocytosis, remained low in TdT+ microglia at 1dpi (Supplementary Figure 4). However, the situation changed at day 4, as we counted 119.1 ± 15.0 microglia per mm2 at the lesion epicenter, which represents a four-fold increase in the number of TdT+ microglia compared to day 1 (Fig. 1g). Microglia around the lesion epicenter exhibited a round morphology, downregulation of P2ry12 and a strong upregulation of CD68 (Supplementary Figures 3 and 4), which points to a potential increase in their phagocytic activity starting around 4 dpi. The number of microglia continued to increase at the lesion epicenter over time, reaching up to 1204.61 ± 137.8 cells/mm2 at 14 dpi. Nearly all microglia observed in these areas were TdT+ CD68hi P2Y12neg (Supplementary Figures 3 and 4). A similar trend was seen in the surrounding tissue (400–800 µm) of the lesion epicenter up to 35 dpi, after which the total number of microglia (i.e. 673.91 ± 62.4 cells/mm2 at the lesion epicenter) started to decrease compared to day 14 (Fig. 1g). Interestingly, TdT+ microglia started to gradually increase their expression of P2ry12 and decrease their expression of CD68 from day 14 up to day 35 (Supplementary Figures 3 and 4), suggesting a partial return to homeostasis. In sum, our data indicate that microglia are rapidly recruited around the site of SCI, where they accumulate extensively during the subacute phase and adopt an activated state that is eventually partially resolved during the intermediate/chronic phases.Fig. 1Microglia proliferate extensively and accumulate at the lesion border after SCI. a–f Confocal immunofluorescence microscopy of representative spinal cord sections showing the spatio-temporal distribution of microglia (TdT, red) and astrocytes (GFAP, cyan) in an uninjured Cx3cr1creER::R26-TdT